Indeed, high-dose celecoxib was associated with a 5.6% greater reduction in the 3-year cumulative incidence of adenomas compared with low-dose celecoxib in patients carrying the SNP rs1057910-C, a genetic variant of cytochrome P450 2C9 (CYP2C9) (Table 2) [98]. This evidence concerns the gene CYP2C9 and adenoma.